Why is "Beclometasone" trending?

Search Interest Perspective

• Chiesi gains pace on climate target with new carbon minimal inhaler data | News - European Pharmaceutical Review
• Filling the gaps in COPD: the TRIBUTE study - The Lancet
• FIGURE 1 - ERS - European Respiratory Society
• Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma | npj Primary Care Respiratory Medicine - Nature
• NHS warns you should do one thing after using inhaler often prescribed for asthma - Daily Record
• NHS alert over who can use beclometasone inhalers for asthma or COPD - Chronicle Live
• NHS alert over inhalers that can contain 'amount of alcohol' - Surrey Live
• Beclometasone–formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial - The Lancet
• One Inhaler Effective for Asthma Triple Therapy - Medscape
• Luforbec® 200/6 (beclometasone 200mcg / formoterol 6mcg) a certified carbon neutral inhaler is launched in the UK for the treatment of adult asthma1,2,3 - lupin.com
• Inhaled Corticosteroids: Managing Side Effects - respiratory-therapy.com
• Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma - NEJM
• Five new medicines backed for EU approval - PharmaTimes
• Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients | Primary Care Respiratory Journal - Nature
• EU Panel Backs Two Triple Combo Drugs for COPD Maintenance - Medscape
• Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease | npj Primary Care Respiratory Medicine - Nature
• EU approves Chiesi’s triple combination asthma therapy Trimbow - PharmaTimes
• Lupin Launches Luforbec® 100/6 for Adult Asthma and COPD Treatment in Germany - Lupin | Press Release - lupin.com
• Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial - The Lancet
• Platelet-derived growth factor D expression in adrenal cells is modulated by corticosteroids: putative role in adrenal suppression - Nature
• Getting used to travelling with Asthma… again - Economy Class & Beyond -
• newsGP - What alternatives are there to FP 50? - Royal Australian College of General Practitioners (RACGP)
• Asthma meds hit the 60-day dispensing list - Medical Republic
• Salbutamol inhaler prescribing jumped 60% at start of COVID-19 pandemic - The Pharmaceutical Journal
• Over 400 people complain of coughing fits after using a new model of inhaler - NL Times
• New COPD medicine launched in China - China Daily
• Lupin Delivers On Generic Fostair With UK Luforbec Launch - Citeline News & Insights
• Generic alternative treatment for asthma & COPD available in UK - Pf Media
• Zeposia, Trimbow and Koselugo are reimbursable in Korea - 의약뉴스
• Trimbow 87/5/9 mcg pressurised inhalation solution recall - Dispensing Doctors' Association
• Lupin gets UK marketing authorisation for Luforbec 100/6 µg pMDI - Express Pharma
• Asthma rescue therapy alone cuts side-effects, study says - GPonline
• Lupin launches Luforbec 100/6 for COPD treatment in Germany - expresshealthcare.in
• Lupin receives UK marketing authorization for Luforbec pMDI - Manufacturing Today India
• Chiesi releases new asthma inhaler batches to meet growing demand - Chemist+Druggist
• FDA delists COVID-19 meds, devices from VAT exemption - Philstar.com
• New asthma inhaler launched - Nursing Times
• FDA removes VAT exemption for Covid-19 medicines, devices - Manila Bulletin